Medical Affairs Policy

Similar documents
Neuropsychological Testing Coverage Guidelines

MEDICAL POLICY No R4 NEUROPSYCHOLOGICAL AND PSYCHOLOGICAL TESTING

ADMINISTRATIVE POLICY AND PROCEDURE

Clinical Policy Title: Neuropsychological testing

Medical Affairs Policy

MEDICAL POLICY SUBJECT: PSYCHOLOGICAL TESTING. POLICY NUMBER: CATEGORY: Behavioral Health

Neuropsychological Testing (NPT)

Psychological & Neuropsychological Test

Medical Affairs Policy

Clinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT)

MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES. Page: 1 of 5

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

Clinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT)

Medical Affairs Policy

Medicare Part C Medical Coverage Policy

Demystifying the Neuropsychological Evaluation Report. Clinical Neuropsychologist 17 March 2017 Program Director, Neurobehavioral Program

Medical Affairs Policy

Medical Affairs Policy

Applied Behavior Analysis for Autism Spectrum Disorders

Related Research. 370 Huntington Hall Syracuse NY (315)

Medical Affairs Policy

MEDICAL POLICY SUBJECT: COGNITIVE REHABILITATION. POLICY NUMBER: CATEGORY: Therapy/Rehabilitation

Cigna Medical Coverage Policy

TESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing

Admission Criteria Continued Stay Criteria Discharge Criteria. All of the following must be met: 1. Member continues to meet all admission criteria

the health outcomes or benefits associated with this procedure.

University of the West Indies, Kingston, Jamaica PLEASE SCROLL DOWN FOR ARTICLE

Medical Affairs Policy

Medical Affairs Policy

Pre and Post Concussion Management

September 12, Richard Hodges Director, Ohio Department of Health 246 N. High St. Columbus, Ohio 43215

Clinical Policy: EEG in the Evaluation of Headache Reference Number: CP.MP.155

Behavioral Health Clinician in Primary Care Billing & Coding Guidance (Created September 2017)

Early Screening of ASD & The Role of the SLP

Arise Medical Policy Updates

Post Concussion Instructions and Return to Play Clearance Form

INTERQUAL BEHAVIORAL HEALTH CRITERIA ADOLESCENT PSYCHIATRY REVIEW PROCESS

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP. PPA.03. Line of Business: Medicaid

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

Sports Neuropsychology: Definition, Qualifications, and Training Guidelines

ATTENTION DEFICIT DISORDER; AEROMEDICAL CONSIDERATIONS

Glenn T. Goodwin, Ph.D. gtgphd.com

Departmental Concussion Guidelines

Reports of the INS - Division 40 Task Force on Education, Accreditation, and Credentialing

Clinical Neuropsychology Residency Program. Department of Health Psychology in the School of Health Professions

01/26/17. Replaces Effective Policy Dated: Autism Spectrum Disorders in Children: Assessment 01/19/16 and Evaluation Reference #: MP/A005 Page 1 of 4

Complete Summary GUIDELINE TITLE

MEDICARE COVERAGE SUMMARY: PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING

Hill, Elisabeth L Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), pp ISSN [Article]

Referrer Resource Pack. Neurocognitive Clinic

Traumatic Brain Injury for VR Counselors Margaret A. Struchen, Ph.D. and Laura M. Ritter, Ph.D., M.P.H.

Docket No CMH Decision and Order

Quality of Life Among Adults with Attention Deficit Hyperactivity Disorder (ADHD): Comparative Study Between the Three Presentations of ADHD

INTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE

No An act relating to health insurance coverage for early childhood developmental disorders, including autism spectrum disorders. (S.

Medical Affairs Policy

Behavioral Health Services An essential, coding, billing and reimbursement resource for psychiatrists, psychologists, and clinical social workers

Michael J. O Brien, MD, Director William P. Meehan III, MD

Using Neuropsychological Experts. Elizabeth L. Leonard, PhD

Dr Mark Fulcher Sports and Exercise Medicine Physician Axis Sports Medicine Specialists

Review of: NATA Position Statement Management of Sport Concussion.

Factors related to neuropsychological deficits in ADHD children

Model Intervention for Students with Substance Abuse Problems Act

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Clinical Policy: Multiple Sleep Latency Testing

The Impact of Autism on Child Development

ADHD Guidance September 2013

TIMOTHY D MCMANUS, PSYD., ABPP-RP, ABN Curriculum Vitae

About Cognition. See Diagnosis Specific Information Section. Autism Spectrum Disorders (ASD) Traumatic Brain Injury (TBI)

Reimbursement Guide. Physical Performance Testing For Balance Assessment. September 18 th, Copyright 2013 Sway Medical LLC

Charles P. Sabatino ABA Commission on Law and Aging May 20, 2009

DIAGNOSIS FOR BAP SUPPLEMENTAL BENEFITS

Version of record first published: 25 Apr 2012.

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether

Role of Neuropsychology Concussion Management. Aimee Custer, PsyD Clinical Sports Neuropsychologist

PEDIATRIC SPORTS RELATED CONCUSSIONS

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Corporate Medical Policy

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

UDS version 3 Summary of major changes to UDS form packets

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED MARCH 14, 2016

Dear Newport News Athletic Parent/Guardian:

Neuropsychological Evaluations of Capacity STEVEN E. ROTHKE, PH.D., ABPP HAYLEY AMSBAUGH, M.S.

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: Last Review Date: Line of Business: Medicaid

Individuals wishing to seek an evaluation for ADHD

Kendra L. Bryant, Ph.D., ABPP- Clinical Neuropsychology EDUCATION Northeastern University Boston College Wellesley College:

NEUROPSYCHOLOGY TRACK COORDINATOR: Dr. Ellen Vriezen

New Study Confirms the Clinical Usefulness of the ImPACT Baseline ImPACT Testing Model VOL. 2 - FALL 2014

NEUROPSYCHOLOGY SERVICE

Behavioral and Early Intervention Reviews/Research

Kendra L. Bryant, Ph.D., ABPP- Clinical Neuropsychology EDUCATION Northeastern University Boston College Wellesley College: CLINICAL EXPERIENCE

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

Finnish practices: Cognitive assessment and interventions

MEDICAL POLICY SUBJECT: NEUROPSYCHOLOGICAL TESTING. POLICY NUMBER: CATEGORY: Contract Clarification

16 SB 319/AP. Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th

Transcription:

Service: Neuropsychological Testing PUM 250-0006 Medical Affairs Policy Medical Policy Committee Approval 03/17/17 Effective Date 07/01/17 Prior Authorization Needed Yes-excluding the neurobehavioral status exam* Disclaimer: This policy is for informational purposes only and does not constitute medical advice, plan authorization, an explanation of benefits, or a guarantee of payment. Benefit plans vary in coverage and some plans may not provide coverage for all services listed in this policy. Coverage decisions are subject to all terms and conditions of the applicable benefit plan, including specific exclusions and limitations, and to applicable state and federal law. Some benefit plans administered by the organization may not utilize Medical Affairs medical policy in all their coverage determinations. Contact customer services as listed on the member card for specific plan, benefit, and network status information. Medical policies are based on constantly changing medical science and are reviewed annually and subject to change. The organization uses tools developed by third parties, such as the evidence-based clinical guidelines developed by MCG to assist in administering health benefits. This medical policy and MCG guidelines are intended to be used in conjunction with the independent professional medical judgment of a qualified health care provider. To obtain additional information about MCG, email medical.policies@wpsic.com. Description: Neuropsychological tests (NPT) are evaluations designed to determine the functional consequences of known or suspected brain injury or abnormality through testing of the neurocognitive domains responsible for language, perception, memory, learning, problem solving and adaptation. Neuropsychological test batteries usually involve extensive evaluation of multiple cognitive domains (e.g., attention, orientation, executive function, verbal memory, spatial memory, language, calculations, mental flexibility, and conceptualization). These tests are carried out on patients who have suffered neurocognitive effects of medical disorders that impinge directly or indirectly on the brain. They are standardized, objective and quantitative in nature and require patients to directly demonstrate their level of competence in a particular cognitive domain. They are not a substitution for clinical interviews, medical, neurologic, or psychological examinations, or other diagnostic procedures used to diagnose neuropathology. Rather, when used judiciously in patients with particular neuropsychological problems, they can be an important tool in making specific diagnoses or prognoses after neurologic injury, to aid in treatment planning, and to address questions regarding treatment goals, efficacy, and patient disposition. Neuropsychological testing is also used to differentiate psychiatric from neurological disorders. Determining what specific brain functions are compromised, as well as which cognitive functions are intact, can help differentiate between the two types of disorders and predict the effects of remediation. Page 1 of 9

Concussion and Post-concussion syndrome: Neuropsychological testing is increasingly used in assessment and management of sport-related concussion to assist in return to play decisions. There is some evidence that testing such as the ImPACT test may help to improve the accuracy of cognitive assessment post-concussion. There is poor evidence that testing is prognostic for rate of recovery or that it should be used alone as an indicator for return to play or school. There is insufficient evidence that baseline tests alone influence physician decision-making or management of concussion. The validity of pre-competition testing is controversial. Neuropsychological testing and Attention Deficit Hyperactivity Disorder: Diagnosis of ADHD can be accomplished using clinical evaluation procedures including an interview, review of the patient s medical, psychological, academic, and/or employment records, information from collateral sources, screening inventories, substance abuse history and physical exam. Neurologic conditions that can mimic or co-occur with ADHD can be distinguished from ADHD through history and medical examination and specialized psychometric and medical testing. Neuropsychological testing may be indicated in rare circumstances. Indications of Coverage: Note: The provider performing the testing must be a covered provider for the particular illness or injury under the plan, depending on the condition that is being evaluated. A. Neurobehavioral status exam is considered medically necessary to evaluate possible issues with cognitive functioning, determine the need for neuropsychological testing, and/ or evaluate the treatment efficacy of a cognitive issue previously diagnosed (not an all-inclusive list). *The neurobehavioral status exam does not require prior authorization. B. Neuropsychological testing (NPT) is considered medically necessary for the purpose of directing further medical care when all of the following criteria are met: 1. Documentation of a neurobehavioral status exam or thorough evaluation by a neurologist, psychiatrist, or psychologist indicates the need for NPT. 2. When at least one medical condition or situation is present such as but not limited to: a. Head injury (open or closed) b. Stroke c. Brain tumor Page 2 of 9

d. Cerebral anoxic or hypoxic episode e. Severe central nervous system infection f. Neoplasm or vascular injury of the central nervous system g. Neurodegenerative disorders (e.g. Lewy body dementia, primary progressive aphasia) h. Demyelinating diseases (e.g., multiple sclerosis) i. Extrapyramidal diseases (e.g., Parkinson s, Huntington s) j. Metabolic encephalopathy after disease stabilization k. Exposure to agents known to be associated with neurodysfunction, (e.g., intrathecal methotrexate, cranial irradiation, lead poisoning). Occupational hazards such as chronic solvent exposure (if a covered benefit) l. A psychiatric diagnosis has been ruled out, or is not responsive to appropriate treatment and testing is requested to provide a differential diagnosis between a psychiatric and neurologic syndrome that is affecting neurocognitive function. (e.g. Complex ADHD with anxiety disorder; autism or other neurodevelopmental disorders, if the diagnosis is in question). m. The presence of unusual, complex, or co-morbid symptoms requiring clarification that only can be accomplished through neuropsychological testing (e.g. worsening symptoms with appropriate treatment for the presumed diagnosis, or differentiating medication related delirium from a progressive process. 3. The neuropsychological tests employed are likely to produce the diagnostic and treatment clarification required and One of the following conditions or situations: a. When there has been a significant mental status change that is not due to a metabolic disorder (such as a diabetic hypoglycemic episode) and the change has not responded to acute medical therapy, OR Page 3 of 9

b. When there has been a significant behavioral change, memory loss, inability to perform simple calculations or abstract tasks, organic brain injury, sensory illusions, or other serious circumscribed cognitive deficits, AND a comprehensive medical and psychological evaluation has been unable to establish a diagnosis OR c. Neurologically complicated cases of Attention Deficit Disorder with significant co-morbidities when, despite a comprehensive medical and psychological evaluation, the diagnosis has not been clearly established, or appropriate medical therapy has failed OR d. Re-evaluation of an individual with decreasing cognitive function is requested due to a neurological disorder if the results are intended to guide treatment. NOTE: Time needed for NPT testing varies depending upon the number of tests performed as well as the cognitive and health status of the individual being tested. More than 8 hours of testing requires physician review. C. Post-Concussion evaluation: Non-baseline NPT testing (e.g. ImPACT) by a physician, psychologist, or licensed mental health professional for management of concussion is considered medically necessary. Limitations of Coverage: A. Review contract and endorsements for exclusions and prior authorization or benefit requirements. B. If used for a condition/diagnosis other than as listed in the Indications of Coverage, deny as experimental, investigational, and unproven at affect health outcomes. C. If used for a condition/diagnosis that is listed in the Indications of Coverage, but the criteria are not met, deny as not medically necessary. If not specified as a health plan exclusion, NPT is considered not medically necessary for any of the following: 1. There is no documentation of thorough medical evaluation by a physician (primary care, specialty, or both) prior to the request. Page 4 of 9

2. Request is solely to confirm the working diagnosis and treatment plan. 3. There is no documentation of how the testing will benefit the development of the treatment plan. 4. Uncomplicated attention deficit disorder with or without hyperactivity (ADD/ADHD). 5. When the individual has been diagnosed with a neuro-developmental disorder (for example, autism or Asperger s syndrome) unless coverage is required by Federal or State mandate. 6. Testing is for requested educational purposes, such as assessment of learning style, learning disability, academic ability, development of an educational plan, or for uncomplicated Attention Deficit Disorder. 7. Testing is for the purpose of obtaining or maintaining employment, or improving job performance. 8. Testing is ordered or requested pursuant to a condition of parole, probation, or in any way related to judicial or legal purposes. 9. Testing is required or requested by a third party, such as a school or place of employment. 10. Testing is solely for documenting or monitoring treatment efficacy. (e.g. Gordon Continuous Performance Test, Test of Variables of Attention, etc. to document effectiveness of ADHD management) 11. Re-testing done within one year without clear clinical justification 12. Baseline neuropsychological testing in asymptomatic persons 13. Routine testing upon admission for a behavioral health condition 14. Testing of members who are currently engaged in substance misuse, are in withdrawal, or who only recently are abstinent from drugs or alcohol, as testing may be unreliable in such situations Documentation Required: Office notes and reports indicating: a. The referral source, and to whom the results will be conveyed. b. The test(s) proposed for evaluation. Page 5 of 9

References: c. The amount of time being requested to complete the evaluation. d. The treatment planning issue that testing is expected to clarify. e. A summary of clinical information, including differential diagnosis, prior evaluation performed to date, and therapies or remediation attempted. 1. American Academy of Clinical Neuropsychology. American Academy of Clinical Neuropsychology (AACN) practice guidelines for neuropsychological assessment and consultation. Clin Neuropsychol. 2007 Mar; 21(2):209-31. 2. American Academy of Pediatrics (AAP). Committee on Quality Improvement, Subcommittee on Attention Deficit/Hyperactivity Disorder. Clinical Practice Guideline: Diagnosis and Evaluation of the Child with Attention Deficit/Hyperactivity Disorder. Pediatrics. 2000; 105(5):1158-1170. 3. American Psychiatric Association. Practice guideline for the Psychiatric Evaluation of Adults. Second Edition. June 2006. Available at: www.psychiatryonline.com/pracguide/pracguidetopic_1.aspx. Accessed: 29 Aug 11. 4. American Psychological Association, Presidential Task Force on the Assessment of Age-Consistent Memory Decline and Dementia (1998). Guidelines for the evaluation of dementia and age-related cognitive decline. Washington, DC: American Psychological Association. Available at: www.apa.org/practice/guidelines/index.aspx. Accessed: 29 Aug 11. 5. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH Jr, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin SW, Tuchman RF, Volkmar FR. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000 Aug 22; 55(4):468-79. 6. Heilbronner RL, Sweet JJ, Attix DK, Krull KR, Henry GK, and Hart RP. Official position of the American academy of clinical neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. 2010. The Clinical Neuropsychologist, 24:8, 1267-1278. Available at: www.tandfonline.com/doi/pdf/10.1080/13854046.2010.526785. Accessed: 29 Aug 11. Page 6 of 9

7. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8; 56(9):1133-42. 8. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention deficit / hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul; 46(7):894-921. 9. Sweet, Jerry J., et al, National Academy of Neuropsychology/Division 40 of the America Psychological Association Practice Survey of Clinical Neuropsychology in the United States, Part I: Practitioner and Practice Characteristics, Professional Activities and Time Requirements: The Clinical Neuropsychologist, 2002, Vol. 2, pp. 109-127 10. Sweet, Jerry J., et al, National Academy of Neuropsychology/Division 40 of the America Psychological Association Practice Survey of Clinical Neuropsychology in the United States, Part II: Reimbursement Experiences, Practice economics, Billing Practices, and Incomes: Archives of Clinical Neuropsychology, 18 (2003) pp. 557582 11. Lundin, Karen A., DeFilippis, Nick A., Proposed Schedule of Usual and Customary Test Administration Times: The Clinical Neuropsychologist, 1999, Vol. 13, No 4, pp. 433-436 12. Camara, Wayne J., et al, Psychological Test Usage: Implications in Professional Psychology: Professional Psychology: Research and Practice: 2000, Vol 31, No 2, pp. 141-154 13. Institute for Clinical Systems Improvement: Health Care Guidelines: Diagnosis and Management of ADHD in Primary Care for School Age Children and Adolescents, Sixth Edition, January 2005 pp. 1-69 14. Hurley, Gina: National Association of Pupil Services Administrators: The Use of Neuroeducational Evaluations in Public Schools, 2001 http://www.napsa.com 15. Hayes Search and Summary: Gordon Diagnostic System to aid in the assessment of ADHD, February 16; 2005 16. Kirkwood MW, Randolph C, Yeates KO. Returning pediatric athletes to play after concussion: the evidence (or lack thereof) behind baseline neuropsychological testing. Acta Paediatr. 2009 Sep; 98(9):1409-11. Page 7 of 9

17. Mayers LB, Redick TS. Clinical utility of ImPACT assessment for postconcussion return-to-play counseling: psychometric issues. J Clin Exp Neuropsychol. 2012; 34(3):235-42. Epub 2011 Dec 13. 18. McCrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, Molloy M, Cantu R. Consensus statement on Concussion in Sport 3rd International Conference on Concussion in Sport held in Zurich, November 2008. Clin J Sport Med. 2009 May; 19(3):185-200. 19. Hayes Search & Summary. Uses for Immediate Post-Concussion Assessment and Cognitive Testing (Impact) after Sports-Related Head Injury. May 16, 2013. 20. UpToDate Concussion and mild traumatic brain injury. Literature review current through: Dec. 20165. This topic last updated: Apr 29, 2015. 21. UpToDate Postconcussion Syndrome. Literature review current through: Dec 2016. This topic last updated: Oct 10 2013. 22. MCG 21 st Edition: ORG: B-805-T (BHG) Neuropsychological Testing. 23. Hayes Medical Technology Directory. Computerized Neurocognitive Testing (CNT) for Sports-Related Head Injury. Publication Date: January 30. 2014, Annual Review Jan 12, 2017. 24. UpToDate Evaluation of cognitive impairment and dementia. Literature review current through: December 2016. This topic last updated: Aug, 3, 2016. 25. UpToDate. ADHD in children and adolescents: Clinical Features and Diagnosis. Literature current through Dec 2016. Topic last updated Jan 04, 2017 26. UpToDate. Concussion in children and adolescents: Management. Literature review current through Dec 2016. Topic last updated Jan11, 2017 27. Gaudet CE and Weyandt LL. Immediate Post-Concussion and Cognitive Testing (ImPACT): a systematic review of the prevalence and assessment of invalid performance. Clin Neuropsychol. 2017 Jan;31(1):43-58. doi: 10.1080/13854046.2016.1220622. Epub 2016 Aug 10. 28. Hang B, Babcock L, Hornung R, et. al. Can Computerized Neuropsychological Testing in the Emergency Department Predict Recovery for Young Athletes With Concussions? Pediatr Emerg Care. 2015 Oct;31(10):688-93. doi: 10.1097/PEC.0000000000000438. Page 8 of 9

WPS / Arise Review History: Implemented 04/04/14, 04/17/15, 07/01/16, 07/01/17 Reviewed 03/07/14, 03/13/15, 03/11/16, 03/17/17 Revised 03/07/14, 03/13/15, 03/11/16, 03/17/17 Developed Medical Policy 03/07/14, 03/13/15, 03/11/16, 03/17/17 Committee Approval Approved by the Medical Director Page 9 of 9